AI Engines For more Details: Perplexity Kagi Labs You
Drowsiness: Orphenadrine can cause drowsiness or sedation, which may impair your ability to perform tasks that require alertness, such as driving or operating machinery. It's essential to avoid activities that require mental alertness until you know how this medication affects you.
Dizziness: Some individuals may experience dizziness or lightheadedness while taking orphenadrine. This side effect can increase the risk of falls, especially in older adults.
Dry mouth: Orphenadrine may cause dry mouth, which can contribute to discomfort or difficulty speaking, swallowing, or tasting food.
Blurred vision: Blurred vision is another common side effect of orphenadrine. It may affect your ability to see clearly and could potentially impair activities such as driving.
Urinary retention: Orphenadrine can interfere with normal bladder function and lead to urinary retention, especially in men with prostate enlargement. This can cause difficulty or inability to urinate.
Constipation: Orphenadrine may cause constipation due to its anticholinergic effects, which can slow down bowel movements and lead to difficulty passing stool.
Nausea and vomiting: Some individuals may experience gastrointestinal side effects such as nausea or vomiting while taking orphenadrine.
Increased heart rate: Orphenadrine can cause tachycardia, or a rapid heart rate, in some individuals. This effect may be more pronounced in individuals with preexisting heart conditions.
Allergic reactions: In rare cases, allergic reactions to orphenadrine may occur, presenting as skin rash, itching, swelling, or difficulty breathing. Seek medical attention immediately if you experience any signs of an allergic reaction.
Cognitive issues: As you mentioned, orphenadrine can cause cognitive impairment, including confusion, memory problems, or difficulty concentrating. This effect may be more significant in older adults.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Bacteroides uniformis | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
| Acne | 0.3 | 0.3 | |
| ADHD | 1.4 | 1.4 | |
| Age-Related Macular Degeneration and Glaucoma | 0.4 | -0.4 | |
| Allergic Rhinitis (Hay Fever) | 1.7 | 0.9 | 0.89 |
| Allergies | 2 | 0.7 | 1.86 |
| Allergy to milk products | 0.7 | 1.3 | -0.86 |
| Alopecia (Hair Loss) | 0.6 | 0.6 | |
| Alzheimer's disease | 2.4 | 2.4 | 0 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.8 | 0.4 | 1 |
| Ankylosing spondylitis | 2.2 | 0.7 | 2.14 |
| Anorexia Nervosa | 0.7 | 1.1 | -0.57 |
| Antiphospholipid syndrome (APS) | 0.7 | 0.3 | 1.33 |
| Asthma | 1.7 | 0.6 | 1.83 |
| Atherosclerosis | 1.2 | 0.6 | 1 |
| Atrial fibrillation | 1.5 | 1.7 | -0.13 |
| Autism | 3.2 | 4.1 | -0.28 |
| Autoimmune Disease | 0.9 | 0.9 | |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 1.3 | 1.3 | |
| Bipolar Disorder | 1.6 | 1.6 | |
| Brain Trauma | 0.3 | 0.3 | 0 |
| Breast Cancer | 0.6 | 0.6 | |
| Cancer (General) | 0.3 | 0.6 | -1 |
| Carcinoma | 2.4 | 0.7 | 2.43 |
| Celiac Disease | 1.8 | 1 | 0.8 |
| Cerebral Palsy | 0.6 | 0.3 | 1 |
| Chronic Fatigue Syndrome | 1.6 | 3 | -0.88 |
| Chronic Kidney Disease | 1.4 | 0.3 | 3.67 |
| Chronic Lyme | 0.3 | -0.3 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.5 | 0.6 | 1.5 |
| Chronic Urticaria (Hives) | 1.3 | 0.3 | 3.33 |
| Coagulation / Micro clot triggering bacteria | 1.7 | 0.3 | 4.67 |
| Cognitive Function | 1 | 0.3 | 2.33 |
| Colorectal Cancer | 4.5 | 1.3 | 2.46 |
| Constipation | 1.5 | 1.5 | |
| Coronary artery disease | 1.7 | 0.6 | 1.83 |
| COVID-19 | 3.6 | 2 | 0.8 |
| Crohn's Disease | 4.4 | 1.3 | 2.38 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 1 | 0.3 | 2.33 |
| d-lactic acidosis (one form of brain fog) | 0.4 | 0.4 | |
| deep vein thrombosis | 1.5 | 0.6 | 1.5 |
| Denture Wearers Oral Shifts | 0.7 | 0.7 | |
| Depression | 5.1 | 3.1 | 0.65 |
| Dermatomyositis | 0.3 | 0.3 | |
| Eczema | 1.3 | 0.8 | 0.63 |
| Endometriosis | 2 | 0.4 | 4 |
| Eosinophilic Esophagitis | 0.3 | 0.3 | 0 |
| Epilepsy | 2.1 | 1.3 | 0.62 |
| erectile dysfunction | 1.3 | 1.3 | |
| Fibromyalgia | 1 | 0.4 | 1.5 |
| Functional constipation / chronic idiopathic constipation | 2.9 | 1.1 | 1.64 |
| gallstone disease (gsd) | 1.8 | 0.3 | 5 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.4 | 0.3 | 3.67 |
| Generalized anxiety disorder | 1.9 | 0.6 | 2.17 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 0.6 | 0.6 | |
| Graves' disease | 0.7 | 0.6 | 0.17 |
| Gulf War Syndrome | 0.3 | 0.3 | 0 |
| Halitosis | 1.1 | 0.3 | 2.67 |
| Hashimoto's thyroiditis | 0.8 | 0.6 | 0.33 |
| Heart Failure | 2.3 | 0 | 0 |
| hemorrhagic stroke | 0.7 | 0.7 | |
| Hidradenitis Suppurativa | 1.2 | 1.2 | |
| High Histamine/low DAO | 0.4 | 0.4 | |
| hypercholesterolemia (High Cholesterol) | 0.4 | 0.4 | |
| hyperglycemia | 1.2 | 0.7 | 0.71 |
| Hyperlipidemia (High Blood Fats) | 0.3 | 0.3 | |
| hypersomnia | 0.3 | -0.3 | |
| hypertension (High Blood Pressure | 2.2 | 1.1 | 1 |
| Hypoxia | 1.7 | 0.1 | 16 |
| IgA nephropathy (IgAN) | 1.3 | 0.2 | 5.5 |
| Inflammatory Bowel Disease | 3.7 | 3.1 | 0.19 |
| Insomnia | 0.8 | 0.9 | -0.13 |
| Intelligence | 0.7 | 0.1 | 6 |
| Intracranial aneurysms | 1 | 1 | |
| Irritable Bowel Syndrome | 2.1 | 1.7 | 0.24 |
| ischemic stroke | 1.4 | 1.2 | 0.17 |
| Liver Cirrhosis | 3.3 | 1.5 | 1.2 |
| Long COVID | 3.1 | 1.6 | 0.94 |
| Lung Cancer | 0.9 | 0.9 | |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1.1 | 1.1 | |
| ME/CFS with IBS | 0.5 | 0.3 | 0.67 |
| ME/CFS without IBS | 0.4 | 0.8 | -1 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.3 | 0.3 | |
| Metabolic Syndrome | 3.5 | 2.5 | 0.4 |
| Mood Disorders | 4.1 | 3.1 | 0.32 |
| multiple chemical sensitivity [MCS] | 0.5 | 0.5 | |
| Multiple Sclerosis | 3 | 2 | 0.5 |
| Multiple system atrophy (MSA) | 0.3 | 0.3 | |
| myasthenia gravis | 0.9 | 0.9 | |
| neuropathic pain | 0.7 | -0.7 | |
| Neuropathy (all types) | 0.3 | 1 | -2.33 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.7 | 0.7 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.9 | 0.3 | 5.33 |
| NonCeliac Gluten Sensitivity | 0.3 | 0.3 | 0 |
| Obesity | 3.3 | 2.7 | 0.22 |
| obsessive-compulsive disorder | 2.9 | 1 | 1.9 |
| Osteoarthritis | 1.3 | 0.6 | 1.17 |
| Osteoporosis | 0.9 | 0.6 | 0.5 |
| pancreatic cancer | 0.5 | 0.3 | 0.67 |
| Parkinson's Disease | 2.8 | 2.1 | 0.33 |
| Polycystic ovary syndrome | 4 | 0.9 | 3.44 |
| Premenstrual dysphoric disorder | 0.4 | -0.4 | |
| primary biliary cholangitis | 0.3 | 0.6 | -1 |
| Primary sclerosing cholangitis | 1.6 | 1.1 | 0.45 |
| Psoriasis | 0.9 | 1.4 | -0.56 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.3 | 0.9 | 1.56 |
| Schizophrenia | 1.6 | 0.7 | 1.29 |
| scoliosis | 0.4 | 0.3 | 0.33 |
| Sjögren syndrome | 1.4 | 1.1 | 0.27 |
| Sleep Apnea | 0.3 | 0.3 | 0 |
| Slow gastric motility / Gastroparesis | 0.7 | 0.7 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.3 | 1.3 | |
| Stress / posttraumatic stress disorder | 1.4 | 0.7 | 1 |
| Systemic Lupus Erythematosus | 2.5 | 2.5 | |
| Tic Disorder | 0.9 | 0.1 | 8 |
| Tourette syndrome | 0.3 | 0.3 | 0 |
| Type 1 Diabetes | 2.3 | 1.2 | 0.92 |
| Type 2 Diabetes | 4.3 | 2.6 | 0.65 |
| Ulcerative colitis | 3.1 | 2 | 0.55 |
| Unhealthy Ageing | 2.6 | 0.5 | 4.2 |
| Vitiligo | 1.3 | 0.4 | 2.25 |
